MLYS - NASDAQ
Mineralys Therapeutics, Inc.
$25.06
-19%Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
At a Glance
Live SnapshotMineralys Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Mineralys Therapeutics, Inc. Balance Sheet
MLYS • NASDAQ
| Mineralys Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
172.9M | 114.1M | 49.3M | 87.7M | 10.6M | 1.4M | |
483.7M | 84.1M | 187.3M | 22.4M | 0.0 | 0.0 | |
656.6M | 198.2M | 236.6M | 110.1M | 10.6M | 1.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 510K | 57K | |
4.8M | 7.2M | 12.5M | 2.7M | 0.0 | 0.0 | |
661.4M | 205.4M | 249.1M | 112.8M | 11.1M | 1.5M | |
NON-CURRENT ASSETS | ||||||
38K | 53K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 2.5M | 0.0 | 0.0 | 0.0 | |
382K | 499K | 51K | 1.6M | 3K | 20K | |
420K | 552K | 2.5M | 1.6M | 3K | 20K | |
661.8M | 205.9M | 251.6M | 114.4M | 11.1M | 1.5M | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
2M | 479K | 601K | 1.9M | 763K | 529K | |
2M | 479K | 601K | 1.9M | 763K | 529K | |
5.5M | 14.2M | 8.3M | 5.5M | 4M | 54K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5M | |
7.6M | 0.0 | 1.6M | 665K | 313K | 0.0 | |
15.1M | 14.6M | 10.5M | 8.1M | 5.1M | 5.1M | |
NON-CURRENT LIABILITIES | ||||||
0.0 | 0.0 | 0.0 | 158.6M | 29M | 0.0 | |
0.0 | 0.0 | 0.0 | 158.6M | 29M | 0.0 | |
15.1M | 14.6M | 10.5M | 166.7M | 34.1M | 5.1M | |
SHAREHOLDERS' EQUITY | ||||||
0.0 | 0.0 | 251.6M | 0.0 | 29M | 0.0 | |
8K | 5K | 4K | 1K | 1K | 1K | |
1.1B | 493.8M | 365.9M | 540K | 85K | 5K | |
-457.2M | -302.5M | -124.7M | -52.8M | -23M | -3.6M | |
0.0 | 0.0 | -251.6M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -29M | 0.0 | |
646.7M | 191.3M | 241.2M | -52.3M | -22.9M | -3.6M | |
646.7M | 191.3M | 241.2M | -52.3M | -22.9M | -3.6M | |
SUMMARY | ||||||
661.8M | 205.9M | 251.6M | 114.4M | 11.1M | 1.5M | |
483.7M | 84.1M | 189.7M | 22.4M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5M | |
-172.9M | -114.1M | -49.3M | -87.7M | -10.6M | 3.1M | |
66,295,857 | 66,295,857 | 66,295,857 | 66,295,857 | 66,295,857 | 66,295,857 |
SEC Filings
MLYS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 |
Related Guides
Continue your MLYS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.